spacer
The Healthcare Sales & Marketing Network celebrates 22 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Parainfluenza 

 HSMN NewsFeed - 14 May 2018
Ansun BioPharma secures $85 million in Series A Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 31 Aug 2011
NexBio's DAS181 (Fludase(R)*) Improves Symptoms in Four Severely Immunocompromised Patients With Life-Threatening Parainfluenza Pneumonitis
Biopharmaceuticals
 HSMN NewsFeed - 24 Mar 2009
FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Feb 2008
Luminex and Abbott Sign Agreement for Global Distribution of the xTAG(TM) Respiratory Viral Panel
Diagnostics Distribution
 HSMN NewsFeed - 3 Jan 2008
Luminex Corporation Receives U.S. Food and Drug Administration Clearance for xTAG(TM) Respiratory Viral Panel
Diagnostics FDA
 HSMN NewsFeed - 2 May 2007
FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Mar 2007
Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in Canada
Biopharmacetuicals
 HSMN NewsFeed - 29 Sep 2006
Efficacy of Once-Daily AVELOX(R) in Treating Complicated Intra-Abdominal Infections Highlighted in Two Clinical Data Presentations at ICAAC
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2006
Study Shows Once-Daily AVELOX(R) as Effective as Multi-Dose Combination Therapy in Treating Complicated Intra-Abdominal Infections
Biopharmaceuticals
 HSMN NewsFeed - 7 Apr 2006
AVELOX(R) Monotherapy as Effective as High-Dose Levofloxacin and Ceftriaxone Combination Therapy in Treating Patients With Severe Community-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 20 Jan 2006
FDA Accepts for Filing Oscient Pharmaceuticals' Supplemental New Drug Application for Five-Day Treatment of CAP with FACTIVE(R) Tablets, Refuses Filing for Five-Day Treatment of ABS
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 24

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 24 additional stories matching:
Parainfluenza
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.